Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News  >  Business Leaders  >  All news

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors 
HomeAll newsMost read newsBusiness Leaders Biography
The feature you requested does not exist. However, we suggest the following feature:

Cerus : to Release Third Quarter 2017 Results on November 2, 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/19/2017 | 02:33pm CEST

Cerus Corporation (NASDAQ:CERS) announced today that its third quarter results will be released on Thursday, November 2, 2017, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the company’s financial results and provide a general business overview and outlook.

To access the live webcast, please visit the Investor Relations page of the company’s website at rel="nofollow" href="http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.cerus.com%2Fir&esheet=51701757&newsitemid=20171019005540&lan=en-US&anchor=http%3A%2F%2Fwww.cerus.com%2Fir&index=1&md5=49a91e9e866ea91f45a589e942568c80">http://www.cerus.com/ir. Alternatively, you may access the live conference call by dialing 866-235-9006 (U.S.) or 631-291-4549 (international).

A replay will be available on the company’s website, or by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and entering conference ID number 82994688. The replay will be available approximately three hours after the call through November 16, 2017.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as Chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See rel="nofollow" href="http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.cerus.com&esheet=51701757&newsitemid=20171019005540&lan=en-US&anchor=http%3A%2F%2Fwww.cerus.com&index=2&md5=ee042b37560910696b72e6dced3b64c8">http://www.cerus.com for information about Cerus.

INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation.

class="bwnowrap">

style='max-width:425px' alt="" src="http://cts.businesswire.com/ct/CT?id=bwnews&sty=20171019005540r1&sid=9129&distro=ftp"/> class="bwct31415"/>

id="mmgallerylink"> id="mmgallerylink-phrase">View source version on businesswire.com: id="mmgallerylink-link"> rel="nofollow" href="http://www.businesswire.com/news/home/20171019005540/en/">http://www.businesswire.com/news/home/20171019005540/en/


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news about
 
1  2  3  4  5  6  7  8  9  10Next

Advertisement